Cornedine J. de Gooijer

T3‐T4 laryngeal cancer in The Netherlands Cancer Institute; 10‐year results of the consistent application of an organ‐preserving/‐sacrificing protocol

Adriana J. Timmermans, Cornedine J. de Gooijer, Olga Hamming‐Vrieze et al. · Head & Neck · 2014 · 58 citations · Full text

Surgical Oncology, Cancer Management, Tonsillectomy +19

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt et al. · The Lancet Respiratory Medicine · 2021 · 47 citations · Full text

First-line Chemotherapy, Switch-maintenance Gemcitabine, Malignant Disease +8

Real life experience with nivolumab for the treatment of non-small cell lung carcinoma

Robert D. Schouten, Mirte Muller, Cornedine J. de Gooijer et al. · Lung Cancer · 2017 · 41 citations

Oncology, Health Sciences, Immune Checkpoint Inhibitor +7

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program

Luca Cantini, Robert A. Belderbos, Cornedine J. de Gooijer et al. · Translational Lung Cancer Research · 2020 · 40 citations · Full text

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma

Daphne W. Dumoulin, Li-Anne H Douma, Maaike M. Hofman et al. · Lung Cancer · 2023 · 27 citations · Full text